In general, antibodies recognizing MAG react with a carbohydrate determinant that is also present on an acidic lipid, sulfoglucuronyl paragloboside. In addition to the anti-MAG ELISA, the anti-SGPG ELISA enhances the chance to detetect all neuropathies. Anti-SGPG antibodies have a wider spectrum than anti-MAG antibodies – some patients which are anti-SGPG positive are negative for anti-MAG antibodies. Therefore, patients should be tested for both antibodies.
The anti-SGPG ELISA from BÜHLMANN is a semi-quantitative assay in which results are compared with a calibrator.
Interestingly, typical sensory demyelinating neuropathies have anti-MAG and anti-SGPG activities, whereas axonal neuropathies present only monoclonal IgM anti-SGPG activity. In humans, there seems to be a relationship between the titer of anti-MAG antibodies and the degree of demyelination.
The presence of anti-MAG/anti-SGPG antibodies is characteristic of a demyelinating neuropathy, whereas the presence of anti-SGPG antibodies alone seems to be more present in axonal non-demyelinating neuropathy, often of predominantly motor-type. Here again, the fine structure of the epitope recognized by the IgM may be involved.
Advantages of BÜHLMANN anti-SGPG antibody ELISA
Uniqueness: The BÜHLMANN anti-SGPG antibody ELISA is worldwide the only CE-marked assay for IVD
Accuracy: Pre-coated microtiter plates.
Specificity: The use of highly purified SGPG results in best likelihood to detect all positive patients.
Using microtiterplate with extremely low unspecific binding properties.
No blocking proteins thus reducing the chance for false positive samples.
Reproducibility: Pre-measured standards and two controls ensure low inter-assay variation.
Anti-SGPG antibody ELISA Product Information
|Time to Result
||4.5 h (approx.)
||2 µl serum (1:1000)
||EK-SGPG 96 wells
* Multilingual [EN, DE, FR, IT, ES]